📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
12 analysed today
FollowTelegram
12
Today
151,874
All-time analysed
43,544
Positive
6,743
Negative
92,750
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
846 announcements match the current filters (relevance ≥ 5).
Biocon Completes Early Redemption of Rs 500 Crore NCDs
Biocon Limited has successfully completed the early full redemption of 50,000 unlisted, secured, rated, redeemable Non-Convertible Debentures (NCDs). The total value of the redemption amounts to Rs 500 Crores, with each NCD having a face value of Rs 1,00,000. The payment was executed on January 05, 2026, following Board approval granted in November 2025. This early repayment indicates a strong liquidity position and will likely reduce the company's future interest expenses.
Key Highlights
Early full redemption of 50,000 unlisted, secured, rated NCDs completed.
Total redemption amount aggregates to Rs 500 Crores.
Face value per NCD was Rs 1,00,000, originally issued in May 2023.
Payment completed on January 05, 2026, ahead of the January 31, 2026 target date.
👀 What to Watch
The early debt repayment is a positive indicator of Biocon's balance sheet strength and cash management. Investors should view this as a move to optimize capital structure and reduce interest costs.
IDBI Bank Q3 FY26 Update: Net Advances Grow 15% YoY to ₹2.38 Lakh Crore
IDBI Bank has released its provisional business updates for the quarter ended December 31, 2025, showing a 12% YoY growth in total business to ₹5,46,634 crore. Net advances grew robustly by 15% YoY to reach ₹2,38,806 crore, indicating strong credit momentum. Total deposits increased by 9% YoY to ₹3,07,828 crore, though CASA deposits saw a slight sequential decline from ₹1,39,036 crore in September 2025 to ₹1,35,630 crore in December 2025. Overall, the bank maintains a steady growth trajectory in its core lending and deposit base.
Key Highlights
Total Business grew 12% YoY to ₹5,46,634 crore as of December 31, 2025
Net Advances increased by 15% YoY to ₹2,38,806 crore from ₹2,06,807 crore
Total Deposits rose 9% YoY to ₹3,07,828 crore compared to ₹2,82,439 crore in the previous year
CASA deposits stood at ₹1,35,630 crore, reflecting a 3.6% YoY growth but a 2.4% sequential decline
👀 What to Watch
Investors should view the strong credit growth positively, but monitor the slight dip in CASA and its impact on the cost of funds in the upcoming full earnings report. The stock remains a watch for further updates on the bank's privatization process alongside these operational improvements.
Rajasthan Govt Rejects Birla Corp's Bid for 499.64 Hectare Limestone Block
The Government of Rajasthan has rejected Birla Corporation's bid for the Gourum Khan Ki Dhani (South) Limestone Block, which spans 499.6394 hectares. Although the company was declared the preferred bidder in June 2025 with a final price offer of 20.60%, the government cited that this bid was lower than those received for similar blocks in the region. The company had already fulfilled procedural requirements and deposited the necessary upfront payments. Birla Corp is now evaluating legal recourse to contest the rejection order dated December 31, 2025.
Key Highlights
Rejection of bid for Gourum Khan Ki Dhani (South) Limestone Block covering 499.6394 hectares.
Final price offer of 20.60% was deemed comparatively lower than other regional auctions.
Company was previously declared the preferred bidder for this block on June 13, 2025.
Management is exploring legal options to challenge the Rajasthan Government's decision.
👀 What to Watch
Investors should monitor the company's legal actions as this rejection impacts long-term raw material security and expansion plans in the Rajasthan region. The loss of this block could necessitate higher costs for future limestone procurement.
Chandrakant Birla Acquires 39.89% Stake in BirlaNu via Inter-se Promoter Transfer
Mr. Chandrakant Birla, a lead promoter of BirlaNu Limited, has consolidated his holding by acquiring 30,07,836 equity shares (39.89% stake) through inter-se transfers. The transaction, executed on December 29, 2025, involved nine promoter group entities transferring their entire holdings to Mr. Birla at an average price of INR 1518.87 per share. While Mr. Birla's individual stake has risen from 0.68% to 40.57%, the total promoter group holding remains unchanged at 40.57%. This move is characterized as an internal restructuring exercise within the promoter group.
Key Highlights
Acquisition of 30,07,836 shares representing 39.89% of the company's equity capital.
Shares acquired at an average price of INR 1518.87 per share via off-market inter-se transfer.
Major sellers include Central India Industries (18.65%) and Shekhavati Investments (7.38%).
Chandrakant Birla's direct ownership increased significantly from 0.68% to 40.57%.
Total promoter and promoter group shareholding remains constant at 40.57%.
👀 What to Watch
As this is an internal restructuring with no change in the aggregate promoter holding, it has no immediate impact on company fundamentals. Investors should view this as a consolidation of control under the primary promoter.
Biocon Shareholders Approve Fundraise and Preferential Share Issuance at EGM
Biocon Limited shareholders have approved all six resolutions proposed at the Extraordinary General Meeting held on December 31, 2025. Key approvals include raising funds through equity or other securities and a preferential issuance of shares for consideration other than cash. Shareholders also authorized an increase in investment and loan limits under Section 186 and cleared material related-party transactions with Mylan Inc. While most resolutions passed with near-unanimous support, the proposal to increase investment limits saw a notable 15.67% dissent from voting participants.
Key Highlights
Approved raising funds in one or more tranches via equity or other securities with 99.13% majority support.
Passed a special resolution for the issuance of equity shares on a preferential basis for non-cash consideration with 99.73% in favour.
Authorized an increase in limits for investments, loans, and guarantees under Section 186 with 84.33% approval.
Cleared material related-party transactions with Mylan Inc. with 99.19% of non-interested votes in favour.
Total voting turnout for the meeting represented approximately 81% of the total share capital.
👀 What to Watch
Investors should monitor the upcoming details regarding the specific terms and pricing of the approved fundraise. The approval for preferential issuance and related-party transactions suggests strategic moves involving its subsidiary, Biocon Biologics.
Biocon EGM Approves Fundraise, Preferential Issue, and Mylan Related Party Transactions
Biocon Limited conducted an Extraordinary General Meeting on December 31, 2025, to pass six key resolutions focused on capital restructuring and growth. Shareholders voted on increasing the authorized share capital and raising fresh funds through equity or other securities in multiple tranches. A significant resolution involved the issuance of equity shares on a preferential basis for consideration other than cash, alongside approval for material related party transactions with Mylan Inc. These moves are designed to strengthen the balance sheet and support the strategic objectives of its subsidiary, Biocon Biologics.
Key Highlights
Approval sought for increasing the Authorised Share Capital and amending the Memorandum of Association.
Proposed raising of funds in one or more tranches through issuance of equity shares or other securities.
Issuance of Equity Shares on a preferential basis for consideration other than cash.
Approval for material related party transactions with Mylan Inc., a related party of Biocon Biologics.
Increased limits for making investments, extending loans, and providing guarantees under Section 186.
👀 What to Watch
Investors should monitor the specific terms of the fundraise and the identity of the preferential allottees to assess potential dilution. The non-cash preferential issue and Mylan transaction suggest a strategic settlement or asset acquisition that could impact long-term valuation.
Chandrakant Birla Acquires 39.89% Stake in BirlaNu via Inter-se Promoter Transfer
Mr. Chandrakant Birla, a promoter of BirlaNu Limited, has acquired a significant 39.89% stake in the company through inter-se transfers from nine other promoter group entities. The transaction involved the acquisition of 30,07,836 shares at a total value of approximately ₹456.85 crore. This move consolidates Mr. Birla's direct individual holding from 0.68% to 40.57%. Since this is an internal transfer within the promoter group, the total promoter shareholding remains unchanged.
Key Highlights
Mr. Chandrakant Birla acquired 30,07,836 equity shares representing 39.89% of the company.
The transaction was executed on December 29, 2025, as an inter-se transfer among promoter group entities.
Major selling entities included Central India Industries (18.65%) and Shekhavati Investments and Traders (7.38%).
The total transaction value is reported at INR 4,56,85,11,865.
Post-acquisition, Mr. Birla's direct stake has increased significantly to 40.57%.
👀 What to Watch
Investors should note that this is a consolidation of holdings within the promoter group and does not change the overall promoter control or public float. No immediate action is required as the company's fundamentals remain unaffected by this internal restructuring.
ESAB India Board Meeting on Feb 10 to Consider Q3 Results and Second Interim Dividend
ESAB India Limited has scheduled a Board Meeting for February 10, 2026, to approve the unaudited financial results for the quarter ended December 31, 2025. Crucially, the board will also consider the recommendation of a second interim dividend for the financial year 2025-26. In accordance with SEBI regulations, the trading window for designated persons will remain closed from January 1, 2026, to February 12, 2026. This announcement provides investors with a clear timeline for upcoming financial performance data and potential income distributions.
Key Highlights
Board meeting scheduled for February 10, 2026, to review Q3 FY26 results.
Consideration of a second interim dividend for the financial year ending March 31, 2026.
Trading window closure for insiders from January 1, 2026, to February 12, 2026.
Results to be published in Business Standard and Makkal Kural newspapers.
👀 What to Watch
Investors should track the February 10 results for margin trends and dividend yield, as the company has a history of consistent payouts.
Panacea Biotec Receives ₹9.38 Crore Income Tax Penalty Demand
Panacea Biotec Limited has received three demand orders from the Income Tax Department totaling ₹9.38 Crore. The penalties are attributed to alleged under-reporting of income for Assessment Years 2017-18, 2020-21, and 2021-22. The company has declared the demand as not maintainable and intends to file an appeal with the appellate authority. While the company does not foresee an immediate operational impact, the final resolution of this litigation will determine the actual financial outflow.
Key Highlights
Aggregate penalty demand of ₹9.38 Crore received from the Assistant Commissioner of Income Tax, Delhi.
Specific demands include ₹5.55 Crore for AY 2017-18, ₹3.11 Crore for AY 2020-21, and ₹0.72 Crore for AY 2021-22.
Penalties imposed under Section 270A of the Income Tax Act, 1961 for alleged under-reporting of income.
Company plans to contest the orders by filing an appeal with the relevant appellate authority.
👀 What to Watch
Monitor the progress of the tax appeal as a negative outcome would result in a cash outflow of ₹9.38 Crore. No immediate action is required as the company is actively contesting the demand.
Panacea Biotec Secures ₹80 Crore Additional Vaccine Supply Orders from UNICEF
Panacea Biotec has received an amendment to its existing contract with UNICEF for the supply of its WHO pre-qualified Pentavalent vaccine, Easyfive-TT®. The total value of the award has been increased by approximately $8.93 million (around ₹80 Crore) for the years 2026 and 2027. Specifically, the 2026 allocation increased by $2.55 million, while the 2027 allocation saw a combined increase and additional award totaling $6.38 million. This development strengthens the company's long-term revenue visibility and reinforces its partnership with international health organizations.
Key Highlights
Total contract value increased by $8.93 million (~₹80 Crore) for CY2026 and CY2027
2026 supply value increased by $2.55 million to a total of $16.8 million
2027 supply value increased by $6.38 million through amendments and additional awards
Supplies involve the WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT®
The contract is with an international entity (UNICEF), ensuring high credit quality
👀 What to Watch
This order provides strong revenue visibility for the next two years and validates the company's standing in the global vaccine market. Investors should monitor the impact on margins and the company's ability to scale production to meet these increased requirements.
Birla Corp Shareholders Approve New Articles of Association Amid Legal Stay
Birla Corporation's shareholders have approved the adoption of a new set of Articles of Association (AoA) at the adjourned 105th AGM held on December 22, 2025. The update aims to align the company's governance framework with the Companies Act 2013 and current SEBI regulations, replacing outdated provisions from the 1956 Act. However, the Calcutta High Court has ordered that the amended AoA shall not take effect for at least one month, pending the disposal of miscellaneous appeals. The final implementation remains contingent on the outcome of these legal proceedings.
Key Highlights
Shareholders approved the adoption of a new set of Articles of Association via a Special Resolution at the adjourned 105th AGM.
The Calcutta High Court has directed that the amended AoA shall not take effect for at least 30 days from December 22, 2025.
The 105th AGM was originally convened on September 15, 2025, and adjourned sine die regarding this specific agenda item.
The governance update is intended to replace redundant articles and align with the Companies Act, 2013 and SEBI LODR regulations.
Implementation of the voting results and subsequent steps are subject to the final outcome of pending Miscellaneous Appeals.
👀 What to Watch
Investors should monitor the resolution of the legal appeals over the next month as the stay indicates potential friction in governance changes. While the update is a standard regulatory alignment, the court's intervention makes it a key monitoring point for corporate governance.
Birla Corp Shareholders Approve New Articles of Association with 78.92% Majority
Birla Corporation Limited has announced the voting results from its adjourned 105th Annual General Meeting held on December 22, 2025. Shareholders approved a special resolution to adopt a new set of Articles of Association with 78.92% of votes in favour. However, following a Calcutta High Court order, the implementation of these changes is stayed for one month pending the disposal of related legal appeals. The significant 21.08% vote against the resolution highlights ongoing friction among stakeholder groups.
Key Highlights
Special resolution for adoption of new Articles of Association passed with 78.92% votes in favour.
A total of 6.43 crore valid votes were polled, with 1.35 crore votes (21.08%) cast against the proposal.
Calcutta High Court directed that the amended Articles shall not take effect for at least one month from December 22, 2025.
The final implementation of the resolution is subject to the outcome of pending Miscellaneous Appeals in the court.
Six specific shareholder accounts were blocked from e-voting at their own request to prevent unauthorized voting attempts.
👀 What to Watch
Investors should monitor the legal developments in the Calcutta High Court as the stay on the new Articles of Association could impact corporate governance structures. The high percentage of 'Against' votes suggests persistent internal or promoter-level disputes that may cause long-term volatility.
Calcutta HC Dismisses Promoter Pleas; Birla Corp to Publish Voting Results on Amended AoA
The Calcutta High Court has dismissed two revisional applications filed by five promoter shareholders against Birla Corporation regarding the amendment of its Articles of Association. The court has permitted the company to publish the voting results for Resolution No. 5, which pertains to these amendments. However, the court mandated a one-month stay on implementing the changes if passed, during which time the lower appeal court must resolve pending Miscellaneous Appeals (No. 303 and 360 of 2025). This development indicates a procedural step forward for the company in a long-standing legal battle involving promoter groups.
Key Highlights
Calcutta High Court dismissed Civil Revisional Applications C.O. No. 4320 and 4338 of 2025 on December 22, 2025.
Company authorized to publish voting results for Resolution No. 5 regarding the adoption of amended Articles of Association.
Implementation of amended AoA is stayed for one month to allow the lower court to dispose of Misc. Appeal Nos. 303 and 360 of 2025.
The final validity of the voting and subsequent steps remains subject to the outcome of the pending Miscellaneous Appeals.
👀 What to Watch
Investors should monitor the publication of the voting results and the subsequent ruling of the appeal court within the next 30 days. The outcome will determine the company's governance structure and the resolution of internal promoter disputes.
Biocon Biologics Secures Full Global Rights for Biosimilar Adalimumab (Hulio)
Biocon Biologics has expanded its agreement with Fujifilm Kyowa Kirin Biologics (FKB) to secure full and exclusive global rights for Hulio (biosimilar Adalimumab). This strategic move transitions Biocon from a commercialization-only partner to an end-to-end owner responsible for manufacturing, development, and commercialization. While Biocon will pay license fees and royalties, FKB will offset certain development costs, which is expected to enhance cost efficiency and operational flexibility. This integration strengthens Biocon's immunology portfolio, which currently serves over 6.3 million patients across 120+ countries.
Key Highlights
Acquisition of full global rights for manufacturing and commercialization of biosimilar Adalimumab (Hulio).
Transition from a commercialization-only model to an end-to-end integrated model for the product.
FKB to offset certain development costs while Biocon pays technology license fees and royalties.
Strategic focus on the immunology portfolio, which currently includes three major biosimilars.
Commercial production at Biocon facilities to commence following technology transfer and regulatory approvals.
👀 What to Watch
This vertical integration is a margin-accretive move that provides Biocon with greater control over its supply chain and product development. Investors should monitor the timeline for technology transfer and regulatory approvals for the in-house manufacturing of Hulio.
Biocon Biologics Secures Full Global Rights for Biosimilar Adalimumab (Hulio)
Biocon Biologics has expanded its agreement with Fujifilm Kyowa Kirin Biologics (FKB) to secure full and exclusive global rights for Hulio (biosimilar Adalimumab). The company will now assume end-to-end responsibility for manufacturing and commercialization, moving beyond its previous role of just commercialization. This strategic shift is designed to improve cost efficiencies and provide greater flexibility in global markets. While Biocon will pay license fees and royalties, FKB will offset certain development costs, supporting the product's long-term growth.
Key Highlights
Secured full global rights for Hulio, including manufacturing and additional development responsibilities.
Agreement supersedes previous collaboration where Biocon Biologics held only commercialization rights.
Biocon Biologics will pay a technology license fee and royalties on sales to FKB for a specified tenure.
FKB will participate in development and offset certain development costs incurred by Biocon Biologics.
Strengthens Biocon's immunology portfolio, which currently serves over 6.3 million patients globally across 120+ countries.
👀 What to Watch
Investors should view this as a margin-accretive move in the long term as Biocon gains manufacturing control; monitor the timeline for regulatory approvals of the new production facilities.
Biocon Issues Commercial Papers Worth Rs 1,800 Crores at 6.85% Interest
Biocon Limited has successfully issued Commercial Papers (CP) worth Rs 1,800 Crores on a private placement basis. The short-term debt instrument carries a competitive interest rate of 6.85% and has a tenure of 88 days, maturing on March 20, 2026. The issue has been subscribed by major institutional investors including SBI Mutual Fund, Axis Mutual Fund, and Aditya Birla Sun Life. The high credit rating of IND A1+ underscores the company's strong short-term credit profile.
Key Highlights
Total issue size of Rs 1,800 Crores via private placement to mutual funds
Short-term tenure of 88 days with maturity scheduled for March 20, 2026
Competitive coupon rate of 6.85% per annum
Assigned a top-tier credit rating of IND A1+ by India Ratings
Proposed to be listed on the National Stock Exchange (NSE)
👀 What to Watch
Investors should view this as a routine short-term liquidity management exercise. The low interest rate and high credit rating indicate strong market confidence in Biocon's financial stability.
Birla Corp Re-convenes Adjourned 105th AGM to Vote on New Articles of Association
Birla Corporation Limited successfully conducted its adjourned 105th Annual General Meeting on December 22, 2025, to address the pending adoption of a new set of Articles of Association. The meeting was previously delayed due to a court injunction, which has since been stayed by the Additional District & Sessions Judge. A total of 477 members attended the meeting, and remote e-voting was conducted between December 19 and December 21, 2025. The final voting results are expected to be disclosed within two working days.
Key Highlights
Adjourned 105th AGM re-convened on Dec 22, 2025, specifically for Item No. 5 regarding new Articles of Association.
The meeting followed a stay order dated Nov 21, 2025, which lifted a previous injunction against the vote.
Remote e-voting was open for shareholders from Dec 19 (9:00 AM) to Dec 21 (5:00 PM), 2025.
A total of 477 members were present in person or through proxy at the Kolkata venue.
Consolidated voting results and the Scrutinizer's Report will be announced within 2 working days.
👀 What to Watch
Investors should monitor the upcoming disclosure of the voting results to confirm the adoption of the new Articles of Association. The resolution of this legal hurdle allows the company to move forward with its updated governance framework.
MobiKwik Seeks Shareholder Nod for Appointment of Radhakrishna Nair as Independent Director
One MobiKwik Systems has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Radhakrishna Nair as a Non-Executive Independent Director. The proposed term is for five years, effective from December 17, 2025, to December 16, 2030. The resolution includes a proposed annual remuneration of ₹17,00,000 for the director. Shareholders can cast their votes through a remote e-voting process that concludes on January 21, 2026.
Key Highlights
Appointment of Mr. Radhakrishna Nair for a 5-year term starting December 17, 2025.
Proposed annual remuneration of ₹17,00,000 plus reimbursement of incidental expenses.
Remote e-voting period runs from December 23, 2025, to January 21, 2026.
Cut-off date for determining shareholder voting eligibility was December 19, 2025.
Special resolution includes approval for the director to continue serving beyond the age of 75 years.
👀 What to Watch
Shareholders should review the appointee's credentials and participate in the e-voting process before the January 21, 2026 deadline. This is a routine governance matter and does not require immediate changes to investment positions.
Chandrakant Birla to Acquire 39.89% Stake in BirlaNu via Inter-se Promoter Transfer
Mr. Chandrakant Birla, a promoter of BirlaNu Limited, is set to acquire 30,07,836 equity shares, representing 39.89% of the company's share capital. This transaction is an inter-se transfer from nine other promoter group entities as part of an internal restructuring exercise. The acquisition is expected to take place on or after December 29, 2025, at a price within the SEBI-prescribed range. Post-acquisition, Mr. Birla's direct stake will rise significantly from 0.68% to 40.57%, though the overall promoter group holding remains unchanged.
Key Highlights
Acquisition of 30,07,836 equity shares representing 39.89% of total share capital
Inter-se transfer among 9 promoter group entities to Mr. Chandrakant Birla
Acquirer's direct holding to increase from 0.68% to 40.57% post-transaction
Transaction price based on 60-day VWAP of INR 1,770.94 per share
Internal restructuring with no change in total promoter group shareholding
👀 What to Watch
This is a routine internal restructuring within the promoter group and does not impact the company's operations or total promoter stake. Investors should treat this as a neutral event with no immediate action required.
Birla Corp Shareholders Reject Appointment of Sudeep Roy as Director; 65.2% Votes Against
Birla Corporation has released the long-delayed voting results for the appointment of Mr. Sudeep Roy as a Non-Executive Non-Independent Director, following a Calcutta High Court order. The special resolution was decisively defeated, with 65.21% of total votes cast against the appointment. Notably, significant opposition came from the promoter group itself (66.14% against) and public institutions (60.28% against), indicating a major lack of consensus on board composition.
Key Highlights
Special resolution to appoint Mr. Sudeep Roy failed with only 34.79% votes in favour.
A total of 3.57 crore votes (65.21%) were cast against the resolution.
Promoter group showed internal division, with 66.14% of their polled votes (2.49 crore shares) against the appointment.
Public institutional investors also rejected the move, with 60.28% of their votes cast against.
The results were released after a two-year delay following the disposal of a legal case (GA/1/2023) by the Calcutta High Court.
👀 What to Watch
Investors should monitor the company for signs of promoter-level conflict or corporate governance issues, as the high 'Against' vote from promoters is unusual. No immediate action is required, but the lack of board consensus warrants a cautious outlook on management stability.
